Log in
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Dynamic quotes 

MarketScreener Homepage  >  Equities  >  Nyse  >  Pfizer    PFE


News SummaryMost relevantAll newsPress ReleasesOfficial PublicationsSector newsAnalyst Recommendations

Pfizer : new JAK inhibitor could come after your eczema market

share with twitter share with LinkedIn share with facebook
share via e-mail
05/17/2019 | 04:55am EDT

Pfizers FDA-approved JAK inhibitor Xeljanz is currently struggling with cardiovascular safety concerns. But another candidate in the family for which Pfizer has blockbuster hopes just slew a phase 3 in atopic dermatitis, teeing up a fight against Sanofi and Regenerons Dupixent.

Abrocitinib, also known as PF-04965842, a JAK1-specific inhibitor, met all co-primary and key secondary endpoints of a late-stage study in moderate to severe eczema patients aged 12 and above, Pfizer said Wednesday.

Specifically, more patients on both doses of the oral Pfizer drug achieved clear or almost clear skin versus placebo after 12 weeks, and a higher percentage of patients saw 75% or greater improvement of eczema from baseline, according to Pfizer. And the drugs benefits already showed during the two to four weeks after the first dose, Pfizer said.

Efficacy aside, industry watchers might also be interested in the drugs safety profile, what with the recent Xeljanz debacle in rheumatoid arthritis that flagged higher cardiovascular risks at a high dosage level.

No detailed data have been provided for abrocitinib, but [s]afety looks good as fewer patients on drug than on placebo stopped therapy due to side effects, Credit Suisse analyst Vamil Divan noted in a memo to clients.

Pfizer is obviously aware of the potential concern. In the only data it has offered, both low and high abrocitinib dose groups saw 5.8% discontinuation due to adverse events, while placebo experienced 9.1%.

The 387-subject trial is the first trial in the drugs atopic dermatitis development program, and data from another study will come out later this year, Pfizer said.

Abrocitinib is one of the 15 in 5 new drug or indication launches before 2022 that Pfizer hopes could eventually reach blockbuster status. Now, the positive phase 3 results are putting it closer to challenging Dupixent.

Dupixent is an effective drug for AD, but it is an injection, and patients usually prefer orals, Cantor Fitzgerald analyst Louise Chen wrote in a Wednesday note to investors.

Dupixent ushered in a new era for moderate-to-severe atopic dermatitis in 2017 when it became the first biologic approved in the indication, and it just recently expanded into adolescents as young as 12. In the first quarter, the drug generated sales of 329 million ($368 million). Though its makers in part have the drug's new asthma indication to thank for the expansion, the eczema market still has much more room for growth.

About two years after launch, Sanofi still considers itself at the very beginning of adult atopic dermatitis, Genzyme chief Bill Sibold said on the companys first-quarter earnings call in April. The drug has reached over 50,000 U.S. patients, he said, only a relatively small proportion of the entire population of 300,000-plus. And the adolescent atopic dermatitis opportunity is about half that size.

Credit Suisse analysts tend to agree; according to their recent analysis of the overall immunology market, atopic dermatitis is far from saturated, with the potential for an additional $7 billion growth opportunity.

(c) 2019 Gulf Sports Media All rights reserved. Provided by SyndiGate Media Inc. (Syndigate.info)., source Middle East & North African Newspapers

Stocks mentioned in the article
ChangeLast1st jan.
PFIZER 0.00% 36.46 Delayed Quote.-16.47%
SANOFI -1.10% 82.8 Real-time Quote.9.44%
share with twitter share with LinkedIn share with facebook
share via e-mail
Latest news on PFIZER
10/18PFIZER : Statement on Vincristine Sulfate Injection, USP Supply in the United St..
10/17PFIZER : Description Amended Statement of Changes in Beneficial Ownership
10/17PFIZER : Description Statement of Changes in Beneficial Ownership
10/15Health-Care Stocks Get a Welcome Respite -- Update
10/15Health-Care Stocks Get a Welcome Respite
10/15Elizabeth Warren's Rise Is Battering Health-Care Stocks
10/15Elizabeth Warren's Rise Is Battering Health-Care Stocks
10/14Health Care Flat As Traders Seek Out Defensive Sectors -- Health Care Roundup
10/14PFIZER : Presents Positive Phase 3 Data at the 28th Congress of the European Aca..
10/14PFIZER : ImaginAb signs multi-party collaboration agreement with three global ph..
More news
Financials (USD)
Sales 2019 51 469 M
EBIT 2019 18 958 M
Net income 2019 13 771 M
Debt 2019 32 534 M
Yield 2019 3,93%
P/E ratio 2019 16,5x
P/E ratio 2020 18,2x
EV / Sales2019 4,55x
EV / Sales2020 4,93x
Capitalization 202 B
Duration : Period :
Pfizer Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends PFIZER
Short TermMid-TermLong Term
Income Statement Evolution
Mean consensus OUTPERFORM
Number of Analysts 14
Average target price 43,15  $
Last Close Price 36,46  $
Spread / Highest target 50,9%
Spread / Average Target 18,4%
Spread / Lowest Target 1,48%
EPS Revisions
Albert Bourla Director, Chief Executive & Operating Officer
Ian C. Read Executive Chairman
Frank A. D'Amelio Chief Financial Officer & EVP-Business Operations
Mikael Dolsten Chief Scientific Officer
Lidia L. Fonseca Chief Technology Officer & EVP
Sector and Competitors
1st jan.Capitalization (M$)
PFIZER-16.47%201 662
JOHNSON & JOHNSON4.74%359 375
ROCHE HOLDING AG18.49%249 453
NOVARTIS15.95%199 827
NOVO NORDISK AS19.37%125 131